(Q37310407)

19 August 2017

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma (English)

1 reference

19 August 2017

1 reference

8

Paul Richardson

1 reference

19 August 2017

4

Ruben Niesvizky

1 reference

19 August 2017

Robert Douglas Knight

16

object named as

Robert D Knight

1 reference

19 August 2017

6

Edward A Stadtmauer

1 reference

19 August 2017

10

Shaji Kumar

1 reference

19 August 2017

Christine Chen

1

1 reference

19 August 2017

Donna E Reece

2

1 reference

19 August 2017

David Siegel

3

1 reference

19 August 2017

Ralph V Boccia

5

1 reference

19 August 2017

Rafat Abonour

7

1 reference

19 August 2017

Jeffrey Matous

9

1 reference

19 August 2017

Nizar J Bahlis

11

1 reference

19 August 2017

Melissa Alsina

12

1 reference

19 August 2017

Robert Vescio

13

1 reference

19 August 2017

Steven E Coutre

14

1 reference

19 August 2017

Dennis Pietronigro

15

1 reference

19 August 2017

Jerome B Zeldis

17

1 reference

19 August 2017

Vincent Rajkumar

18

1 reference

19 August 2017

language of work or name

English

0 references

publication date

26 May 2009

1 reference

British Journal of Haematology

19 August 2017

1 reference

19 August 2017

146

1 reference

19 August 2017

2

1 reference

19 August 2017

164-170

1 reference

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

A phase 2 study of bortezomib in relapsed, refractory myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Antitumor activity of thalidomide in refractory multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

2 September 2018

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

Lenalidomide and venous thrombosis in multiple myeloma

1 reference

12 December 2020

Multiple myeloma. Clinical practice guidelines in oncology

1 reference

12 December 2020

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

12 December 2020

10.1111/J.1365-2141.2009.07728.X

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

1 reference